Q1 2027 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Key Points
- Dr Reddy's Laboratories Ltd (RDY) reported healthy double-digit growth in its underlying base business across key geographies, including North America.
- The company successfully launched several key complex generic products, such as Bosutinib in the United States and semaglutide in Canada and India.
- Dr Reddy's Laboratories Ltd (RDY) achieved significant milestones in its access agenda, including securing Thai FDA approval for Zoliflodacin, a first-in-class treatment for uncomplicated gonorrhea.
- The company maintained a strong cash position with a net cash surplus of INR3,057 crores (USD323 million) as of June 30, 2026.
- Dr Reddy's Laboratories Ltd (RDY) continues to focus on strengthening its base business and building future growth engines in peptides, biosimilars, consumer health, and innovation.
- The company experienced a revenue decline of 5.6% year-over-year, primarily due to lower lenalidomide sales and semaglutide API-related challenges.
- EBITDA margin was adversely impacted, standing at 12.5% for the quarter, reflecting the semaglutide-related issues and Middle East conflict.
- The SG&A expenses increased by 12% year-over-year, driven by higher personnel costs, adverse ForEx movements, and elevated freight costs.
- Dr Reddy's Laboratories Ltd (RDY) faced challenges in the US market with a decline in North America revenue due to lower lenalidomide sales.
- The company encountered regulatory challenges, receiving a Form 483 with seven observations from the US FDA at its biologics manufacturing facility.
'--
Good day, everyone and welcome to quarter 1 FY27 earnings call of Dr. Reddy's Laboratories Limited. We appreciate your continued interest in our company. I'm Aishwarya Sitharam, Head of Investor Relations at Dr. Reddy's.
Joining us today are members of the leadership team, Mr. Erez Israeli, our Chief Executive Officer; and Mr. M.V. Narasimham, MVN, our Chief Financial Officer. Our quarterly financial results have been published earlier today and are available on our website for your reference.
We will start today's call with MVN providing an overview of our financial performance for the quarter. Following that, Erez will share his insights on key business highlights as well as the company's strategic outlook. We will then open the floor for questions.
All commentary and analysis during this call are based on our IFRS consolidated financial statements. Please note that certain non-GAAP financial measures may also be discussed. Reconciliations to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
